A good, succinct overview from today's Pharma Compliance Blog of QbD's past and where it stands today, from Gary Miller of CIS Partners.
--Paul Thomas
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Search This Blog
Blogs Related to QbD and Drug Development
Related Content
About PharmaQbD Blog
- Paul Thomas
- Senior Editor of Pharmaceutical Manufacturing magazine, PharmaQbD.com, and PharmaManufacturing.com
Posts
Blog Archive
-
▼
2009
(75)
-
▼
July
(26)
- Can PCMO and PQLI Work in Harmony for Paradigm Cha...
- ADAPT Agenda Set; Throckmorton to Speak
- QbD Presentations on Parade: DynoChem's User Meeting
- How Varian Complements Agilent for QbD
- QbD for Biopharma: New Course at PDA FDA Joint Con...
- Wiley Publishes QbD for Biopharma, Edited by Ratho...
- What Is the Real Meaning of Pharma Innovation?
- Snooping Around: A Peek at Quality Management at S...
- H1N1 Puts Onus on Industry to Embrace QbD and FDA'...
- Can QbD Help Build Better Partnerships?
- Risk Management Strategies for Extractables and Le...
- The QbD/Six Sigma Connection, Revisited
- Mulling Adaptive Clinical Trial Design, and Hula H...
- Biosensors in Clinical Trials: More from John Lowr...
- QbD in a Nutshell
- White Paper: Operational Efficiency in Clinical Tr...
- Innovation: Are You in a Dynamic Ocean or Shrinkin...
- On the Horizon: Drug Discovery and Development Week
- How QbD Can Leverage Outsourcing Partnerships
- Pharmaceutical Allies: QbD and Six Sigma
- Quality Risk Management in Jersey
- Progressive Collaborations: GSK Gets First Contrib...
- Public and Private: Janssen Alliance for TB Drug D...
- Real-Time Neurochemical Monitoring of Trial Patients?
- Microsoft's Les Jordan on DIA 2009
- Blue Reference's Van Eikeren Outlines QbD and Othe...
-
▼
July
(26)
No comments:
Post a Comment